FDA Backs 23andMe Tests For Breast Cancer Risks
The U.S. Food and Drug Administration said Tuesday it will allow genetics research company 23andMe to conduct new direct-to-consumer testing of three mutations in a gene that are associated with higher...To view the full article, register now.
Already a subscriber? Click here to view full article